Navigation Links
Argos Confirms Improved RNA Amplification Protocol Enhances Quality of Antigen-Specific Immune Response
Date:5/8/2013

DURHAM, N.C., May 8, 2013 /PRNewswire/ -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced the publication of key findings on its proprietary RNA amplification process. The study confirms the Company's improved RNA amplification techniques enhance the quality of the resultant antigen-specific immune response.

The study, which was published in the May issue of Molecular Therapy-Nucleic Acids, a companion journal to Molecular Therapy, evaluated the properties of renal cell carcinoma RNA after amplification and following introduction into dendritic cells using newly developed tests. Investigators found that the improved amplification process resulted in superior protein expression levels and a greater capacity of dendritic cells to induce a strong T-cell response.

"The new RNA amplification techniques we have developed further validate Argos Therapeutics' leadership in the field of RNA-containing therapeutics," said Charles Nicolette , Ph.D., Chief Scientific Officer and Vice President of Research and Development of Argos Therapeutics. "With the ADAPT Phase 3 study for AGS-003 well underway, the improved amplification process should help to provoke stronger immune responses in study patients and ultimately lead to positive clinical outcomes."

By tracking specific antigens, researchers were able to demonstrate that the protein antigens were produced inside dendritic cells transfected with the amplified RNA. It was further shown that RNA amplified using the improved process resulted not only in higher levels of antigen expression but also in greater numbers of antigen-specific memory T cell responses. In a completed Phase 2 study with AGS-003, this specific type of immune res
'/>"/>

SOURCE Argos Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argoss Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
2. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
3. Collegium Announces Results of Chronic Pain Patient Survey - Confirms Significant Unmet Medical Need for a Differentiated, Abuse-Deterrent, Extended-Release Opioid
4. New CDC Study Confirms Effectiveness of UV-C Disinfection in Reducing Harmful Pathogens for Hospitals
5. Lilly Confirms Date and Conference Call for First-Quarter 2013 Financial Results Announcement
6. Perrigo Confirms First to File Patent Challenge for Generic Version of Testosterone Gel 1.62%
7. Perrigo Confirms FDA Approval For Testosterone Gel 1%
8. New Analysis Confirms Albumin Preserves Kidney Function and Improves Survival in Common Abdominal Infection of Liver Disease
9. Beth Israel Deaconess Medical Center, Harvard Medical School Study Confirms Cannabis Sciences Approach to Development of CS-TATI-1 to Inhibit Kaposi Sarcoma
10. Quest Diagnostics Confirms Investor Day on November 16
11. TUV Rheinland Confirms Apparent Fraud in Mislabeling of DRX Products Manufactured by HTRD and Excite Medical
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... -- According to a new market research ... Type (Protein & Genetic Biomarkers) Profiling Technology (Proteomics, Genomics, ... - Global Forecast to 2020", published by MarketsandMarkets, The ... Million USD by 2020 at a CAGR of 13.9% ... Browse 191 Tables and 38 F ...
(Date:8/28/2015)... , Aug. 28, 2015 ... has announced the addition of the "12th ... and Production" report to their offering. ... of Biopharmaceutical Manufacturing Capacity and Production is the ... manufacturing organizations, current and projected future capacity and ...
(Date:8/28/2015)... WARRENVILLE, Ill. , Aug. 28, 2015 /PRNewswire/ ... Patterson Companies, Inc. (Nasdaq: PDCO ), is ... the previously announced acquisition of Patterson Medical by ... Medical will retain its name for a transition ... distributor of rehabilitation and sports medicine products.  With ...
Breaking Medicine Technology:Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 2Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 3Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 4Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 512th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 3
... Inc., a biotechnology company developing orally-available antiviral therapeutics, today ... Officer, will present at two upcoming investor conferences in ... on November 16th at 10:30 am at The Pierre ... Conference on November 29 at 11:50 am at The ...
... 2011 PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial ... 2011. (Logo:   http://photos.prnewswire.com/prnh/20111025/LA93174LOGO-c ) ... were $6.0 million, 3% higher than sales of $5.8 ... to increases in sales of the Company,s medical device ...
Cached Medicine Technology:Chimerix to Present at Upcoming Lazard and Piper Jaffray Healthcare Conferences 2Chimerix to Present at Upcoming Lazard and Piper Jaffray Healthcare Conferences 3Pro-Dex, Inc. Announces Fiscal 2012 First Quarter Results 2Pro-Dex, Inc. Announces Fiscal 2012 First Quarter Results 3Pro-Dex, Inc. Announces Fiscal 2012 First Quarter Results 4Pro-Dex, Inc. Announces Fiscal 2012 First Quarter Results 5
(Date:8/30/2015)... CA (PRWEB) , ... August 30, 2015 , ... ... Focused Ultrasound (HIFU) medical devices for the treatment of prostate cancer, has announced ... introduced this summer at the treatment center in Puerto Vallarta, Mexico. , The ...
(Date:8/29/2015)... ... August 30, 2015 , ... Electronic ... 1:30 p.m. – 3:00 p.m. EDT, http://www.fdanews.com/electronicinformedconsent , The simple fact ... handwritten signature. , Clinical trial sites can now use audio, video ...
(Date:8/29/2015)... , ... August 29, 2015 , ... ... insufficient scrotal support and protection against dribbled urine and sweat. "In order to ... Hills, N.Y. , The EASY ACCESS DRYNESS ENHANCED MEN'S UNDERGARMENT provides optimal support ...
(Date:8/29/2015)... ... ... like Toppik , Eau Thermale Avene and Bliss are now available on ... required to qualify for free standard shipping,” said Jennifer Ramirez, the public relations manager. ... the item’s selling price.” , With competitive pricing in the e-commerce market for beauty ...
(Date:8/29/2015)... ... 2015 , ... People who have heart or lung diseases, ... are at higher risk from wildfire smoke especially in Calgary, Alberta.Those with existing ... (arrhythmia or irregular heartbeat) are also sensitive to air pollution. , Tiny ...
Breaking Medicine News(10 mins):Health News:Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 3Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 4Health News:Modified Men’s Underwear Promote More Comfort and Hygiene - Designed by InventHelp Client (LGI-1968) 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2
... that pelvic imaging using computed tomography (CT) examinations are ... and eliminating this exam can significantly reduce a patient,s ... the pelvis during CT pulmonary angiography does not improve ... author for this study. He asserts, "Using CT venography ...
... FOR DETERMINING SOURCE OF ACUTE SHORTNESS OF BREATH ... replace standard chest x-ray as the first choice of ... source of acute dyspnea is needed. Italian researchers studied ... strong agreement between the results of chest ultrasonography and ...
... Inhaled Beta-agonists Increase Survival Over Anticholinergics ... agents are commonly prescribed to manage chronic obstructive ... to decrease exacerbations and hospitalizations and improve COPD ... mortality. However, it is not known which therapy ...
... HealthDay Reporter , MONDAY, May 2 (HealthDay News) -- The ... than the brains of normally developing children, and the difference ... The finding is a follow-up to earlier research that found ... of similarly aged normally developing kids, researchers said. ...
... Reporter , MONDAY, May 2 (HealthDay News) -- Kids who ... up getting injured more often, new research suggests. ... pursuit were almost twice as likely to get hurt as ... Neeru Jayanthi, medical director of primary care sports medicine at ...
... May 2 (HealthDay News) -- American workers forced to travel ... study suggests. A team of U.S. researchers found that ... are at higher risk for cardiovascular disease than "light" travelers who ... The team at Columbia University,s Mailman School of Public Health analyzed ...
Cached Medicine News:Health News:Chest journal news briefs, May 2011 issue 2Health News:Embargoed news from Annals of Internal Medicine 2Health News:Embargoed news from Annals of Internal Medicine 3Health News:Brains of Autistic Kids Still Larger at Age 4, 5 2Health News:Brains of Autistic Kids Still Larger at Age 4, 5 3Health News:Kids Specializing in One Sport More Likely to Get Hurt: Study 2Health News:Kids Specializing in One Sport More Likely to Get Hurt: Study 3Health News:Frequent Business Travel Tough on the Heart, Study Finds 2
... 6 is an enzyme immunoassay (EIA) test ... various specific nuclear antigens (SS-A, SS-B, RNP/Sm, ... is used as an aid in the ... connective tissue disease (MCTD), Sjgren's syndrome and ...
The 8500 is an extremely reliable portable pulse oximeter, requiring no periodic maintenance or calibration....
The PalmSAT® 2500 series are small, yet versatile digital pulse oximeters for accurate assessment of blood oxygen saturation and pulse rate. Choose alarm or non-alarm versions for your portable ...
The pocket-size Invacare Digit finger pulse oximeter is a convenient and economical solution to fast, reliable SpO2, pulse rate and pulse strength measurements. Its compact size is ideal for home use...
Medicine Products: